TBAJ-587   Click here for help

GtoPdb Ligand ID: 13060

Synonyms: compound 8 [PMID: 30803745]
PDB Ligand
Compound class: Synthetic organic
Comment: TBAJ-587, an analogue of bedaquiline, was discovered at the University of Auckland following a lead optimization programme to identify novel members of the diarylquinolines class of antibacterial compounds [2]. TBAJ-587 has a more favourable ADME profile, lower risk of QT prolongation, and more potent antimycobacterial activity than bedaquiline [2].
See also our entry for TBAJ-876 that was identified in the same study.

TBAJ-587 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 1
Rotatable bonds 11
Topological polar surface area 85.11
Molecular weight 614.5
XLogP 1.55
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CN(C)CC[C@@](C1=CC(=NC(=C1)OC)OC)([C@H](C2=CC=CC(=C2F)OC)C3=C(N=C4C=CC(=CC4=C3)Br)OC)O
Isomeric SMILES CN(C)CC[C@@](C1=CC(=NC(=C1)OC)OC)([C@H](C2=C(C(=CC=C2)OC)F)C3=C(N=C4C=CC(=CC4=C3)Br)OC)O
InChI InChI=1S/C30H33BrFN3O5/c1-35(2)13-12-30(36,19-16-25(38-4)34-26(17-19)39-5)27(21-8-7-9-24(37-3)28(21)32)22-15-18-14-20(31)10-11-23(18)33-29(22)40-6/h7-11,14-17,27,36H,12-13H2,1-6H3/t27-,30-/m1/s1
InChI Key JJEGOJPMKLRSPJ-POURPWNDSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
TBAJ-587 is under clinical development as an oral treatment for TB. A Phase 1 study, to evaluate safety, tolerability, and pharmacokinetics in healthy adults (NCT04890535), has been completed (last update May 2023).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Functionally, TBAJ-587 inhibits mycobacterial ATP synthase [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04890535 Evaluation of the Safety, Tolerability, PK of TBAJ-587 in Healthy Adults Phase 1 Interventional Global Alliance for TB Drug Development